The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review Denise M.

Slides:

Advertisements

Similar presentations

Early Stem Cell Transplantation for Refractory Acute Leukemia after Salvage Therapy with High-Dose Etoposide and Cyclophosphamide Asha Johny, Kevin W.

Advertisements

Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic.

Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

How to Treat MDS without Stem Cell Transplantation

Nonmyeloablative conditioning for relapsed follicular lymphoma

Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors Mitchell S. Cairo,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Allogeneic Bone Marrow Transplantation for Low-Grade Lymphoma

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Chimerism-Based Pre-Emptive Immunotherapy with Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation.

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors Kenneth.

A 15-Year Analysis of Early and Late Autologous Hematopoietic Stem Cell Transplant in Relapsed, Aggressive, Transformed, and Nontransformed Follicular.

Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Sabina Kersting, Leo F. Verdonck

Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular.

Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children’s Oncology Group Study A5962

Betty T. Tran, Abigail Halperin, Jason W. Chien

Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Gita Thanarajasingam, Haesook T. Kim,

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma Peter Dreger, Ginna.

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Mitchell S. Cairo, Willi Woessmann, John Pagel

Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report.

Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients.

John Kuruvilla, John D. Shepherd, Heather J. Sutherland, Thomas J

Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies Robert.

Kasiani C. Myers, Stella M. Davies

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia George L. Chen, Hong Liu,

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma Christopher Parrish, Amin Rahemtulla, Jim.

High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphoma (PTCL): Analysis of Prognostic Factors Auayporn Nademanee,

High-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma Lisa Y. Law,

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Willis H. Navarro, Fausto R.

A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Improved Outcomes after Autologous Bone Marrow Transplantation for Children with Relapsed or Refractory Hodgkin Lymphoma: Twenty Years Experience at a.

What is quality in a transplant program?

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Myelodysplastic Syndromes: An Evidence-Based Review Denise.

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

Blood and Marrow Transplant Handbook

Koen van Besien, Jeanette Carreras, Philip J. Bierman, Brent R

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: An evidence-based review Theresa Hahn,

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Mammen Chandy Biology of Blood and Marrow Transplantation

Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia,

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based.

Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma∗ Theresa Hahn, Philip L. McCarthy,

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Presentation transcript:

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review Denise M. Oliansky, Leo I. Gordon, Jerry King, Ginna Laport, John P. Leonard, Peter McLaughlin, Robert J. Soiffer, Koen W. van Besien, Michael Werner, Roy B. Jones, Philip L. McCarthy, Theresa Hahn Biology of Blood and Marrow Transplantation Volume 16, Issue 4, Pages 443-468 (April 2010) DOI: 10.1016/j.bbmt.2010.01.008 Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 The probability of EFS for patients in the two treatment arms. This research was originally published in Blood, Ladetto et al., 2008 [9]. Reprinted with permission. © 2008 the American Society of Hematology. All rights reserved. Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 The probability of EFS for patients in the two treatment arms. This research was originally published in Blood, Sebban et al., 2006 [11]. Reprinted with permission. © 2006 the American Society of Hematology. All rights reserved. Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 PFS after high-dose radiochemotherapy followed by ASCT or IFN-α maintenance in follicular lymphoma. This research was originally published in Blood, Lenz et al., 2004 [12]. Reprinted with permission. © 2004 the American Society of Hematology. All rights reserved. Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 The probability of PFS for patients in the three treatment arms. Schouten et al., 2003 [17]. Reprinted with permission. © 2003 American Society of Clinical Oncology. All rights reserved. Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Comparison of overall survival between patients treated with Cy+TBI and control group. Rohatiner et al., 2007 [19]. Reprinted with permission. © 2007 American Society of Clinical Oncology. All rights reserved. Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 6 Probabilities of disease-free survival by type of transplant, adjusted for significant covariates. This research was originally published in Blood, van Besien et al., 2003 [20]. Reprinted with permission. © 2003 the American Society of Hematology. All rights reserved. Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 7 Actuarial probability of DFS for low-grade lymphoma patients according to type of transplant. Bierman et al., 2003 [21]. Reprinted with permission. © 2003 American Society of Clinical Oncology. All rights reserved. Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 8 Estimated EFS for patients who underwent PBSCT with (R+) or without (R–) rituximab according to disease status. (A) Patients receiving PBSCT first-line therapy. (B) Patients receiving PBSCT as salvage therapy for refractory disease or early relapse. Tarella et al., 2008 [26]. Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved. Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 9 DFS in low-grade lymphoma patients by pre-SCT rituximab (R group) versus no rituximab (NR group). Hoerr et al., 2004 [27]. Reprinted with permission. © 2004 American Society of Clinical Oncology. All rights reserved. Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10 Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10 Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10 Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10 Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10 Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10 Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10 Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10 Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10 Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10 Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10 Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10 Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10 Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10 Biology of Blood and Marrow Transplantation 2010 16, 443-468DOI: (10.1016/j.bbmt.2010.01.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions